{"id":"tislelizumab-plus-carboplatin-and-paclitaxel","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tislelizumab works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby unleashing an immune response against the cancer. Carboplatin and paclitaxel, on the other hand, are cytotoxic agents that induce DNA damage and apoptosis in rapidly dividing cancer cells.","oneSentence":"Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:00.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT07416474","phase":"PHASE3","title":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":574},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT07131319","phase":"PHASE2, PHASE3","title":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-04-21","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT07111455","phase":"","title":"Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-07-22","conditions":"Locally Advanced Oral Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT05014815","phase":"PHASE2","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-11-16","conditions":"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV","enrollment":272},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT06091943","phase":"PHASE1","title":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-16","conditions":"Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT07046221","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Esophagus Cancer","enrollment":60},{"nctId":"NCT07068178","phase":"PHASE2","title":"Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Jing Li","startDate":"2025-08","conditions":"HIPEC, Ovarian Serous Adenocarcinoma","enrollment":30},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06969612","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":21},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT06977074","phase":"PHASE2","title":"PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-10","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":83},{"nctId":"NCT06978829","phase":"PHASE2","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-03-01","conditions":"LA HNSCC","enrollment":42},{"nctId":"NCT06965829","phase":"PHASE2","title":"The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Esophageal Cancer Stage III","enrollment":40},{"nctId":"NCT06939127","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT04906382","phase":"EARLY_PHASE1","title":"Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer","status":"TERMINATED","sponsor":"Floor Backes, MD","startDate":"2021-07-01","conditions":"Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma","enrollment":2},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT06703047","phase":"PHASE2","title":"Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03594747","phase":"PHASE3","title":"A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-07-30","conditions":"Non-Small Cell Lung Cancer","enrollment":360},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT05628610","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-09-30","conditions":"Esophageal Cancer","enrollment":130},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06323369","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":154},{"nctId":"NCT05582265","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-10-28","conditions":"Head and Neck Squamous Cell Carcinomas","enrollment":537},{"nctId":"NCT06366945","phase":"PHASE2","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC","enrollment":85},{"nctId":"NCT06357598","phase":"PHASE4","title":"Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-01-18","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT06235918","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xiang Lu","startDate":"2023-01-01","conditions":"Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma","enrollment":30},{"nctId":"NCT05611879","phase":"PHASE2","title":"Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-03-12","conditions":"NSCLC, Stage III","enrollment":30},{"nctId":"NCT06136910","phase":"PHASE1, PHASE2","title":"Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-05-09","conditions":"Untreated Advanced Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06056336","phase":"PHASE2","title":"Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Guo Xufeng","startDate":"2023-09-07","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy","enrollment":73},{"nctId":"NCT05990127","phase":"PHASE3","title":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2023-11-14","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":642},{"nctId":"NCT05791097","phase":"PHASE3","title":"Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT05809895","phase":"PHASE2","title":"Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2023-09-15","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT05900921","phase":"PHASE2","title":"Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2023-07-01","conditions":"Advanced Squamous Non-Small-Cell Lung Cancer","enrollment":132},{"nctId":"NCT05863260","phase":"","title":"Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-11-09","conditions":"Cervical Cancer, Immune Checkpoint Inhibitor, Chemoradiotherapy","enrollment":60},{"nctId":"NCT05777707","phase":"PHASE1, PHASE2","title":"Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2020-10-29","conditions":"Esophageal Carcinoma, Neoadjuvant Immunotherapy","enrollment":89},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05596890","phase":"PHASE2","title":"Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-11-30","conditions":"Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy","enrollment":50},{"nctId":"NCT05245760","phase":"PHASE2","title":"ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer","status":"WITHDRAWN","sponsor":"Zhonglin Hao","startDate":"2022-04","conditions":"Esophageal Cancer, Esophagogastric Junction Cancer","enrollment":""},{"nctId":"NCT05247619","phase":"PHASE2","title":"A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-06-30","conditions":"Cervical Cancer","enrollment":49},{"nctId":"NCT04973306","phase":"PHASE2, PHASE3","title":"Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-02","conditions":"Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III","enrollment":176},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT05244837","phase":"PHASE2","title":"Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC","status":"UNKNOWN","sponsor":"Hao Long","startDate":"2020-12-22","conditions":"Tislelizumab, Safety, Biomarker","enrollment":100},{"nctId":"NCT05207904","phase":"PHASE2","title":"Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-06-17","conditions":"Non-Small Cell Squamous Lung Cancer, Brain Metastases","enrollment":41},{"nctId":"NCT04405674","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-07-15","conditions":"Non Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT05024266","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-08-01","conditions":"Lung Squamous Cell Carcinoma, Neoadjuvant Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT05013268","phase":"PHASE1","title":"Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-09","conditions":"Cervical Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT04815408","phase":"PHASE2","title":"PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1","enrollment":40},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tislelizumab plus Platinum-Based Chemotherapy"],"phase":"phase_3","status":"active","brandName":"Tislelizumab plus Carboplatin and Paclitaxel","genericName":"Tislelizumab plus Carboplatin and Paclitaxel","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}